Amplia Therapeutics Limited (ASX:ATX)

Market Cap	114.66M
Revenue (ttm)	3.78M
Net Income (ttm)	-6.57M
Shares Out	388.67M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,439,048
Average Volume	11,153,394
Open	0.2450
Previous Close	0.2350
Day's Range	0.2450 - 0.3000
52-Week Range	0.0490 - 0.2950
Beta	0.69
RSI	76.75
Earnings Date	Aug 27, 2025

About Amplia Therapeutics

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ATX

Financial Performance

In 2024, Amplia Therapeutics's revenue was 3.78 million, a decrease of -15.03% compared to the previous year's 4.45 million. Losses were -6.57 million, 45.9% more than in 2023.